Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication (TREAT): protocol for a multicenter, open-label, non-inferiority, randomized controlled trial
The trial was registered on the Chinese Clinical Trial Registry (ChiCTR2400089979) on 20th September 2024.
Authors
- Nianshuang Li (ORCID: https://orcid.org/0000-0001-7343-9311)
- Xin Xu (ORCID: https://orcid.org/0000-0002-7954-7900)
- Yong Xie (ORCID: https://orcid.org/0000-0002-6589-7854)
- Cong He (ORCID: https://orcid.org/0000-0002-1185-5456)
- Xu Shu (ORCID: https://orcid.org/0000-0002-0861-5742)
- Nonghua Lü (ORCID: https://orcid.org/0000-0003-4373-551X)
- Yin Zhu (ORCID: https://orcid.org/0000-0002-7561-2306)
- Yi Hu (ORCID: https://orcid.org/0009-0009-4532-0685)
Institutions
- First Affiliated Hospital of Jiangxi Medical College (CN)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1177/17562848251366374
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Key Research and Development Program of Jiangxi Province